A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...
One of the most recognized features of No Child Left Behind is subgroup analysis, which shifted attention from the average performance of a school to the performance of specific populations within a ...
In the dynamic world of clinical trials, innovative methods are vital to improving the efficiency and reliability of medical research. One area that has garnered both interest and scepticism is ...
Author(s)Goadsby PJ, Reuter U, Hallströ, m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017, 377(22):2123-2132. doi: 10.1056/NEJMoa1705848. Certain medications ...
Delcath Systems (DCTH) announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication was published in ...
This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...
In the pharmaceutical research field, the journey from laboratory to pharmacy shelf is fraught with challenges, such as the high failure rates and increasing costs of clinical trials. Significant ...
– Cabozantinib reduced the risk of disease progression or death by 50 percent compared with placebo in patients with advanced gastrointestinal neuroendocrine tumors – – Supplemental New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback